Traws Pharma, Inc. TRAW
0.24 USD +0.01 (+3.94%)
Regular-session close
0.24 0.00 -0.62%
After hours · Nov 18, 6:25 PM ET
0.2319 Day range 0.259
0.22 52-week range 3.23
- YTD
- -78.54%
- 1 year
- -88.62%
News
benzinga.com Traws Pharma Q3 EPS $(0.18) Beats $(0.20) Estimate Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 47.06 percent increase over losses of $(0.34)…
globenewswire.com Traws Pharma Reports Third Quarter 2026 Financial Results and Provides Business Highlights NEWTOWN, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, “Traws Pharma,” “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies for…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session. enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market…
benzinga.com Traws Pharma Advances Oral COVID-19, Monthly Flu Antiviral Toward Next Milestones Traws Pharma Inc. (NASDAQ:TRAW) announced final Phase 2a clinical data for its investigational oral COVID-19 therapy ratutrelvir alongside completed bridging and toxicology studies for its…
benzinga.com Traws Pharma Advances Oral COVID-19, Monthly Flu Antiviral Toward Next Milestones Traws Pharma reports positive Phase 2a ratutrelvir COVID-19 results and completes key tivoxavir marboxil flu studies ahead of FDA talks.benzinga.com Traws Pharma Reports Final Phase 2a COVID-19 Data, Advances Influenza Candidate Ratutrelvir, a once-daily, ritonavir-free oral antiviral therapy in development for COVID-19 infections, showed symptom resolution time comparable to PAXLOVID®, with no viral rebound through Day 28…
globenewswire.com Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID® Ratutrelvir , a once-daily, ritonavir-free oral antiviral therapy in development for COVID-19 infections, showed symptom resolution time comparable to PAXLOVID ® , with no viral rebound through Day…benzinga.com Traws Pharma Enters $50M Committed Equity Purchase Agreement With Roth Principal Investments; May Issue And Sell Up To 135,135,135 Shares Of Common Stock Traws Pharma, Inc.Up to 135,135,135 Shares of Common StockThis prospectus relates to the resale by Roth Principal Investments, LLC, a Delaware limited liability company ("Roth Principal Investments"…
defenseworld.net Comparing Gyre Therapeutics (NASDAQ:GYRE) and Traws Pharma (NASDAQ:TRAW) Gyre Therapeutics (NASDAQ: GYRE - Get Free Report) and Traws Pharma (NASDAQ: TRAW - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the…
globenewswire.com Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights NEWTOWN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to…
defenseworld.net Traws Pharma (NASDAQ:TRAW) Shares Up 4.8% – Here’s What Happened Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shares shot up 4.8% during mid-day trading on Monday. The stock traded as high as $0.4871 and last traded at $0.4716. Approximately 94,244 shares…
globenewswire.com Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed Resubmission of updated data package to MHRA, expected in 3Q 2026, to…
benzinga.com Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program.
globenewswire.com Traws Pharma Provides Regulatory Update on Influenza Program NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral…
globenewswire.com Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low…
globenewswire.com Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027
benzinga.com Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak Traws Pharma, Inc. (NASDAQ:TRAW) shares are up during Friday's session, trading higher by 25.86% as the company is advancing potential clinical candidates for the treatment of hantavirus infections.
globenewswire.com Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to…
zacks.com Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement…
seekingalpha.com Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript
globenewswire.com Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,
defenseworld.net Traws Pharma (NASDAQ:TRAW) Shares Up 8.8% – Should You Buy? Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shot up 8.8% on Monday. The stock traded as high as $1.64 and last traded at $1.61. 21,635 shares were traded during trading, a decline of 60% from…
globenewswire.com Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution;…
globenewswire.com Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic…
prnewswire.com ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials SAN DIEGO , Oct. 30, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services…
